This review synthesizes recent advances in diagnostic, surveillance, prognostic, and treatment-predictive biomarkers, with emphasis on assay principles, analytical platforms and reported performance where available, and delineates critical barriers to translation.
Abstract
Bladder cancer (BC) is a prevalent malignancy characterized by a high recurrence rate and the necessity for long-term surveillance demands, creating a need for accurate yet practical tools for early detection and monitoring. While current standards including cystoscopy, urinary cytology, and imaging remain indispensable, their clinical utility is constrained by invasiveness, suboptimal sensitivity for selected lesions or low-grade lesions, inter-observer variability, and cumulative costs. Currently, biomarker research has expanded from single protein assays to multi-analyte strategies encompassing DNA, RNA, proteins, extracellular vesicle-associated cargo, and metabolomics signatures. This review synthesizes recent advances in diagnostic, surveillance, prognostic, and treatment-predictive biomarkers, with emphasis on assay principles, analytical platforms and reported performance where available. Furthermore, we delineate critical barriers to translation, including limited prospective multicenter validation, heterogeneous pre-analytical workflows, inconsistent thresholds, and the persistent trade-off between sensitivity and specificity in real-world benign urologic conditions. Ultimately, while emerging biomarkers and multi-omics panels hold transformative potential as non-invasive adjuncts in risk-adapted clinical pathways, their routine adoption is contingent upon rigorous clinical integration and standardized validation.
Urothelial carcinoma is a common urinary malignancy with high incidence, recurrence, and mortality. Early diagnosis is pivotal for improving patient outcomes. Current standards have important limitations: cystoscopy, although the cornerstone of diagnosis and surveillance, is invasive and costly, while cytology has limi...
Shu-Xin Li, Lei Wang, Bao-Shan Gao· Frontiers in Oncology· 0 citations
Bladder cancer (BC), as the most common form of urothelial carcinoma, represents a substantial global health burden owing to its high rates of late diagnosis and disease recurrence. Current standard diagnostics, such as cystoscopy and tissue biopsy, are invasive, costly, and limited in capturing tumor heterogeneity or...
Can Chen, Yu-Ze Yang, Zhou-Hui Chen et al.· Journal of Translational Med...· 0 citations
Multibiomarker integration, supported by prospective validation and automated models, represents a promising approach to personalize treatment algorithms in early-stage TNBC, balancing efficacy and toxicity while guiding escalation and de-escalation strategies.
Federica Falcone, E. Pietroluongo, P. De Placido· Current Opinion in Oncology· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed after the opportunity for curative treatment has passed. Blood-based biomarkers offer opportunities for earlier detection and serial molecular assessment, but their value depends on the intended clinical use. This nonsystematic narrative review critically exami...
Konstantinos Kossenas, N. Garmpis, Nikolaos Karountzos et al.· Frontiers in Oncology· 0 citations
Liquid biopsy is a minimally invasive approach to early detection and biomarker assessment in gynecological cancers. This structured review synthesizes evidence on circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomal non-coding RNAs, epigenetic markers (methylation and fragmentation), and multi-omics...